Pre-op chemoradiotherapy ups survival in esophageal cancer

May 31, 2012
Pre-Op chemoradiotherapy ups survival in esophageal cancer
For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine.

(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine.

Peter van Hagen, M.C.C.M., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues investigated the role of neoadjuvant chemoradiotherapy in the treatment of 366 patients with resectable esophageal or esophagogastric-junction cancer (275 with , 84 with squamous-cell carcinoma, and seven with large-cell undifferentiated carcinoma). Participants, enrolled from March 2004 through December 2008, were randomly allocated to receive surgery alone (188 patients) or to receive carboplatin and paclitaxel for five weeks with concurrent radiotherapy, followed by surgery (178 patients).

The researchers found that 92 percent of patients in the chemoradiotherapy-surgery group achieved complete resection with no tumor within 1 mm of the resection margins, compared with 69 percent in the surgery-alone group. Twenty-nine percent of patients who underwent resection after chemoradiotherapy achieved a pathological complete response. In the two treatment groups, were similar, with 4 percent in-hospital mortality in both groups. The median overall survival was 49.4 and 24.0 months in the chemoradiotherapy-surgery and surgery-alone groups, respectively. In the chemoradiotherapy-surgery group, overall survival was significantly improved (hazard ratio, 0.657; P = 0.003).

"Preoperative chemoradiotherapy (five courses of and , with 41.4 Gy of concurrent radiotherapy) is safe and leads to a significant increase in overall survival among patients with adenocarcinoma or squamous-cell carcinoma of the esophagus or esophagogastric junction," the authors write.

Explore further: Early response is an indicator for rectal cancer survival

More information: Full Text (subscription or payment may be required)

Related Stories

Early response is an indicator for rectal cancer survival

April 10, 2012
(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

Chemotherapy and radiation given together could help elderly patients with lung cancer live longer

May 21, 2012
Despite more than two-thirds of lung cancer cases being diagnosed in people 65 years or older, there have been few trials of treatments in this age group, and it is not known if the standard treatment for patients with inoperable ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.